Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ascendis Pharma A/S - American Depositary Shares (NQ:ASND)

213.99 +7.54 (+3.65%)
Streaming Delayed Price Updated: 10:06 AM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ascendis Pharma A/S - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
A Glimpse of Ascendis Pharma's Earnings Potential ↗
 
Via Benzinga
News headline image
Why ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) could fit Mark Minervini’s high-growth criteria ↗
A fundamental and technical analysis of (NASDAQ:ASND): Is ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) suited for high growth investing? 
Via Chartmill
News headline image
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
Does ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) show the characteristics of a Minervini super stock? ↗
A fundamental and technical analysis of (NASDAQ:ASND): Why the high growth investor may take a look at ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND). 
Via Chartmill
News headline image
Looking Into Ascendis Pharma's Recent Short Interest ↗
 
Via Benzinga
News headline image
Here's How Much $100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
Here's How Much $100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 12, 2025 ↗
 
Via Benzinga
News headline image
Is ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) a Minervini-style stock? ↗
A fundamental and technical analysis of (NASDAQ:ASND): Why the high growth investor may take a look at ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND). 
Via Chartmill
News headline image
Why Is BioMarin Stock Trading Higher On Thursday? ↗
BioMarin exceeded Q4 earnings expectations, raised 2025 guidance, and projected strong Voxzogo growth. Analysts increased price targets following the results. 
Via Benzinga
News headline image
Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday? ↗
Ascendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath's EU launch. Goldman Sachs raised its price target. 
Via Benzinga
News headline image
Ascendis Pharma Eyes Best Open In A Month After Q4 Print, But BofA Cuts Price Target: Retail Gets Buzzing ↗
The brokerage adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp. 
Via Stocktwits
News headline image
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years ↗
 
Via Benzinga
News headline image
Looking Into Ascendis Pharma's Recent Short Interest ↗
 
Via Benzinga
News headline image
Peering Into Ascendis Pharma's Recent Short Interest ↗
 
Via Benzinga
News headline image
(ASND) - Analyzing Ascendis Pharma's Short Interest ↗
 
Via Benzinga
News headline image
A Glimpse of Ascendis Pharma's Earnings Potential ↗
 
Via Benzinga
News headline image
This Coca-Cola Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
Can BioMarin Stock Live Up to Wall Street’s High Expectations?
BioMarin has greatly improved the fundamentals of its business, but continues losing value. Is the tide ready to turn, or is more of the same on the horizon? 
Via MarketBeat
News headline image
Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts? ↗
Novo Nordisk is expected to report third-quarter earnings on Wednesday. Stock up 8.55% in a year, 7.45% year-to-date. 
Via Benzinga
News headline image
Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug ↗
Ascendis Pharma and Novo Nordisk sign exclusive global license for TransCon technology, aiming to advance obesity, type 2 diabetes, and cardiovascular treatments. 
Via Benzinga
News headline image
If You Invested $100 In This Stock 15 Years Ago, You Would Have $5,600 Today ↗
 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years ↗
 
Via Benzinga
News headline image
Looking Into Ascendis Pharma's Recent Short Interest ↗
 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 14, 2024 ↗
 
Via Benzinga
News headline image
BioMarin's Pipeline Faces Skepticism As Analyst Questions Future Growth ↗
BioMarin posts Q3 EPS of $0.91, nearly doubling last year's $0.46 and topping estimates. Sales rose 28%, driven by strong Voxzogo growth. Analyst downgrades on lack of upcoming catalysts. 
Via Benzinga
News headline image
3 Oversold Stocks with Big RSI Rebound Potential
Everybody loves finding a bargain or getting a good deal, and it's no different when it comes to stocks. The RSI indicator is a great way to find them. 
Via MarketBeat
Topics Economy
News headline image
BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish ↗
BioMarin Pharmaceutical aims to achieve $4 billion in revenue by 2027, driven by Voxzogo adoption, despite emerging competition from Ascendis Pharma. Goldman Sachs maintains a "Buy" rating with a $139... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.